Over the past three decades, the development of β-lactamase inhibitors has been crucial in combating β-lactam resistance. β-lactam antibiotics, such as penicillins, cephalosporins, monobactams, and carbapenems, work by inhibiting bacterial cell wall synthesis. However, β-lactamases, enzymes produced by bacteria, can inactivate these antibiotics, leading to resistance. To counter this, β-lactamase inhibitors have been developed to either prevent the inactivation of β-lactam antibiotics or to create new β-lactam antibiotics that are resistant to β-lactamases. β-lactamase inhibitors are classified into several categories, including clavulanic acid, sulbactam, and tazobactam, which are commonly used in clinical practice. These inhibitors work by binding to the active site of β-lactamases, preventing them from inactivating β-lactam antibiotics. However, some β-lactamases, such as class A enzymes, have developed resistance to these inhibitors through specific mutations, such as substitutions at key residues like Arg244, Met69, Asn276, and Ser130. To address this challenge, researchers have explored the development of novel β-lactamase inhibitors, including monobactam derivatives, ATMO derivatives, penems, and other non-β-lactam inhibitors. These new inhibitors aim to extend the lifespan of current β-lactam antibiotics and may also serve as novel β-lactam antibiotics in the future. Additionally, inhibitors targeting metallo-β-lactamases, such as thiol derivatives and phosphonates, are being investigated. The mechanisms of β-lactamase inhibition involve various strategies, including the use of β-lactam-β-lactamase inhibitor combinations, which are effective in clinical settings. These combinations have been shown to be particularly useful against Gram-negative bacteria, where β-lactamases are commonly produced. However, resistance to these inhibitors is a growing concern, especially with the emergence of inhibitor-resistant class A β-lactamases. In conclusion, the development of β-lactamase inhibitors has been essential in maintaining the effectiveness of β-lactam antibiotics. As resistance continues to evolve, the need for new and more effective inhibitors remains critical. Ongoing research into novel inhibitors and their mechanisms of action is vital to ensuring the continued success of β-lactam therapy.Over the past three decades, the development of β-lactamase inhibitors has been crucial in combating β-lactam resistance. β-lactam antibiotics, such as penicillins, cephalosporins, monobactams, and carbapenems, work by inhibiting bacterial cell wall synthesis. However, β-lactamases, enzymes produced by bacteria, can inactivate these antibiotics, leading to resistance. To counter this, β-lactamase inhibitors have been developed to either prevent the inactivation of β-lactam antibiotics or to create new β-lactam antibiotics that are resistant to β-lactamases. β-lactamase inhibitors are classified into several categories, including clavulanic acid, sulbactam, and tazobactam, which are commonly used in clinical practice. These inhibitors work by binding to the active site of β-lactamases, preventing them from inactivating β-lactam antibiotics. However, some β-lactamases, such as class A enzymes, have developed resistance to these inhibitors through specific mutations, such as substitutions at key residues like Arg244, Met69, Asn276, and Ser130. To address this challenge, researchers have explored the development of novel β-lactamase inhibitors, including monobactam derivatives, ATMO derivatives, penems, and other non-β-lactam inhibitors. These new inhibitors aim to extend the lifespan of current β-lactam antibiotics and may also serve as novel β-lactam antibiotics in the future. Additionally, inhibitors targeting metallo-β-lactamases, such as thiol derivatives and phosphonates, are being investigated. The mechanisms of β-lactamase inhibition involve various strategies, including the use of β-lactam-β-lactamase inhibitor combinations, which are effective in clinical settings. These combinations have been shown to be particularly useful against Gram-negative bacteria, where β-lactamases are commonly produced. However, resistance to these inhibitors is a growing concern, especially with the emergence of inhibitor-resistant class A β-lactamases. In conclusion, the development of β-lactamase inhibitors has been essential in maintaining the effectiveness of β-lactam antibiotics. As resistance continues to evolve, the need for new and more effective inhibitors remains critical. Ongoing research into novel inhibitors and their mechanisms of action is vital to ensuring the continued success of β-lactam therapy.